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An urgent call for a stronger, louder voice for TB vaccine advocacy1. Background
In 1993 the World Health Organization (WHO) declared tuber-
culosis (TB) a Global Emergency. Almost twenty years later the TB
incidence in South Africa is still 993/100 000.1 South Africa has
one of the highest rates of TB per capita.1 Globally TB is now the
leading cause of death for persons living with HIV, causing one in
four deaths.
A novel TB vaccine is urgently needed, as the only licensed TB vac-
cine, BCG, developed over ninety years ago and widely used for in-
fants globally, exhibits variable protective beneﬁt against
pulmonary TB and has failed to control the global epidemic. Since
2005,more than $650million has been invested in the global TB vac-
cine pipeline allowing more than ﬁfteen vaccine candidates to be
evaluated in more than 50 human trials, many of which have been
conducted in South Africa, led by South African researchers and insti-
tutions.2 The most clinically advanced candidate in the current pipe-
line has shown no protection against TB disease or infection in a
phase IIb trial recently completed.3 However, a robust pipeline of
pre-clinical and clinical candidates and progress in identifying corre-
lates of protection suggest that theworld remains on target to have a
new, more universally effective vaccine against TB as soon as within
the next decade.4
The global economic crisis has negatively impacted the funding
of health research.5 Researchers and advocates must unite to
educate policy makers about the need for new TB vaccines and
the role they can play in supporting TB vaccine research and devel-
opment (R&D).
At the recent South African TB Conference held in Durban in
June 2012, two sessions were organized jointly by Emergent Bio-
solutions, Aeras, South African Tuberculosis Vaccine Initiative
(SATVI), Aurum Institute and the South African Medical Research
Council (MRC) to address gaps and challenges in building stake-
holder participation in the TB vaccine arena and to formulate a
common message for TB vaccine R&D in order to increase aware-
ness, political will and resources for new vaccines. These sessions
brought together researchers, public health programme ofﬁcials,
members of civil society and representatives of international orga-
nizations to discuss vital interactions between stakeholders. The
participants in these sessions emphasized that advocacy is a crucial
component in TB R&D and that TB vaccines will have a critical
impact on achieving key Millennium Development Goals. Re-
sources and support are needed to rapidly advance novel TB vaccine
candidate research and development from discovery research to
clinical trials through to licensure and distribution. Both advocates
and researchers have a role to play in increasing awareness. It is1472-9792 2013 Elsevier Ltd.
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Open access under CC BY-NC-ND license.important that common credible messages are used and that they
are delivered correctly.
2. Strong key messages emerged from the two sessions
BCG alone is not enough to control the TB epidemic.
The community and relevant stakeholders must understand
that while BCG as a vaccine has lifesaving beneﬁts for infants
against certain severe forms of TB6 it has variable protective beneﬁt
in adolescents and adults against pulmonary TB, themost prevalent
and infectious form of the disease.7,8
It is hoped that this knowledge will result in communities
engaging more deeply and generating greater societal demand
and political will for TB vaccine development. Stakeholders are
similarly underinformed of the facts surrounding the TB epidemic,
the consequences of drug-resistant strains, and progress made over
the past decade in TB vaccine R&D. New TB vaccines would need to
protect equally well against drug-resistant and drug-sensitive
forms of TB.
The solution to the TB epidemic must include new TB vac-
cines as well as new diagnostics and drugs.
It should be emphasized that the TB vaccine community sup-
ports a multidimensional approach towards tackling the TB
epidemic and that new TB vaccines acting synergistically with
novel, shorter, TB drug regimens and faster, simpler TB diagnostics
are required to eliminate TB as a global public health problem. It is
also important to manage expectations. Wemust be clear about the
timelines involved in vaccine research. Our messages should make
it clear that we are still researching novel vaccine candidates and
their safety and efﬁcacy still needs to be established.
Increased resources for TB vaccine development and advo-
cacy are needed.
To successfully develop effective TB vaccines, resources must
be made available for all levels of TB vaccine research, from pre-
clinical to clinical to introduction. It is critical that TB advocates
regardless of whether working at community level, regionally,
nationally or globally lobby for more resources to fund commu-
nity outreach initiatives. Increasing the number of TB vaccine
advocates will help create the required critical mass to bring
about change. From the HIV advocacy community, advocates
can learn about awareness campaigns using mass volunteers
which helped to demystify clinical trials for the community
and resulted in antiretroviral drugs being made affordable.
The countries carrying the burden of disease need to be part-
ners in the solution.
Taking into account the high TB burden in SADC’s Southern
African member countries, SADC should show commitment to
Letter to the Editor / Tuberculosis 93 (2013) 277–278278TB vaccine R&D. The drive for a new TB vaccine should also be
coming from affected countries and not only from the north:
we should “own the agenda”. The “south” may have less re-
sources, but not intellectual capacity. SADC countries should pri-
oritize funding for vaccine R&D as well as community
engagement and advocacy programmes. Commitment should
also be in the form of a facilitative regulatory environment
that provides clear guidance to vaccine developers and helps
ensure vaccine safety, which will encourage vaccine research
and the subsequent registration and distribution of a safe, effec-
tive TB vaccine.
There is a need for increased coordination, collaboration and
communication between all stakeholders.
To help governments understand the potential beneﬁts of fund-
ing TB R&D, vaccine advocacy groups together with therapeutics
and diagnostics groups should develop a robust evidence base
around the cost of TB to society and the potential beneﬁts and sav-
ings to health systems from a vaccine to prevent pulmonary TB.
3. Conclusion
Substantial progress is being made in TB vaccine R&D, yet to
maintainmomentum and ensure that the robust pipeline continues
to expand and strengthen, evidence-based messages must be
developed on the global, national, regional and community levels
to help inform, engage and mobilize decision makers, inﬂuentials
and civil society groups. Personal stories should be used to make
the messages real and memorable so that they will be absorbed
and repeated. It is only through insistent, well-informed, advocacy
that wewill be able to provide the necessary resources and political
will to move TB vaccines through clinical trials, into licensure, and
ultimately to those who need them most, to protect against all
forms of tuberculosis, including drug-resistant strains.
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